Achieve Life Sciences Stock (NASDAQ:ACHV)
Previous Close
$3.61
52W Range
$3.42 - $5.59
50D Avg
$4.42
200D Avg
$4.64
Market Cap
$121.05M
Avg Vol (3M)
$122.88K
Beta
1.58
Div Yield
-
ACHV Company Profile
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
ACHV Performance
Peer Comparison
| Ticker | Company |
|---|---|
| BOLT | Bolt Biotherapeutics, Inc. |
| APLS | Apellis Pharmaceuticals, Inc. |
| TCRX | TScan Therapeutics, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| IMMX | Immix Biopharma, Inc. |
| ITOS | iTeos Therapeutics, Inc. |
| NXTC | NextCure, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| HEPA | Hepion Pharmaceuticals, Inc. |
| CHRS | Coherus BioSciences, Inc. |
| CNSP | CNS Pharmaceuticals, Inc. |
| SPRO | Spero Therapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |